

**REPORT TO THE TWENTY-EIGHTH HAWAII STATE LEGISLATURE
2016**

**IN ACCORDANCE WITH THE PROVISIONS OF
SECTION 346-59.9, HAWAII REVISED STATUTES,
ON PSYCHOTROPIC MEDICATION**

**DEPARTMENT OF HUMAN SERVICES
MED-QUEST DIVISION
OCTOBER 2015**

**2015 ANNUAL REPORT ON PSYCHOTROPIC MEDICATION,
SECTION 346-59.9, HAWAII REVISED STATUTES.**

Act 102, Session Laws of Hawaii (SLH) 2012, amended section 346-59.9, Hawaii Revised Statutes (HRS), Psychotropic Medication. Section 346-59.9 (g) (HRS), requires the Department of Human Services to report annually on:

- (1) The number of brand-name and generic prescriptions written to which this section applies; and
- (2) The amount expended on brand-name prescriptions and the amount expended on generic prescriptions written each fiscal year to which this section applies.

The information is provided in the tables below.

Hawaii Medicaid Psychotropic Cost for Fiscal Year 2015*

| | | Total Number of Claims | | | | Total Expenditure | | | |
|----------------|----------------|------------------------|-----|---------|------|-------------------|-----|-------------|-----|
| | | Brand | | Generic | | Brand | | Generic | |
| | | # | % | # | % | \$ | % | \$ | % |
| Antipsychotic | | | | | | | | | |
| | 7/1/14-6/30/15 | 26,539 | 35% | 48,338 | 65% | \$25,284,317 | 74% | \$8,983,030 | 26% |
| Antidepressant | | | | | | | | | |
| | 7/1/14-6/30/15 | 5,621 | 5% | 116,059 | 95% | \$1,448,199 | 32% | \$3,108,626 | 68% |
| Anti-anxiety | | | | | | | | | |
| | 7/1/14-6/30/15 | 86 | <1% | 59,163 | 100% | \$61,879 | 12% | \$437,611 | 87% |

* Includes QUEST Integration (QI) Health Plans, Community Care Services (CCS) and Fee-For-Service (FFS). State fiscal year (FY) 2015 is the first full year of data for Ohana CCS.

The total cost for psychotropic medication in FY 2015 is approximately \$34,300,000. The QI Health Plans (\$ 20,900,000) and the CCS program (\$13,400,000) accounted for the vast majority of costs in FY 2015. The Fee-For-Service cost for psychotropic medication is negligible.

Hawaii Medicaid Psychotropic Cost: Quest Integration and Fee-For-Service

| | | Total Number of Claims | | | | Total Expenditures | | | |
|-----------------------|---------------------|------------------------|-----|---------|------|--------------------|-----|-------------|-----|
| | | Brand | | Generic | | Brand | | Generic | |
| | | # | % | # | % | \$ | % | \$ | % |
| Antipsychotic | | | | | | | | | |
| | 7/1/2009-6/30/2010 | 41,568 | 77% | 12,279 | 23% | \$20,120,498 | 93% | \$1,462,845 | 7% |
| | 7/1/2010-6/30/2011 | 44,771 | 76% | 13,863 | 24% | \$25,292,347 | 95% | \$1,399,257 | 5% |
| | 7/1/2011-6/30/2012 | 36,942 | 60% | 24,660 | 40% | \$23,577,237 | 81% | \$5,392,685 | 19% |
| | 7/1/2012-6/30/2013 | 24,124 | 38% | 38,545 | 62% | \$18,854,977 | 78% | \$5,343,676 | 22% |
| | 7/1/2013-6/30/2014 | 17,543 | 38% | 29,109 | 62% | \$15,400,608 | 81% | \$3,501,443 | 19% |
| | 7/1/2014-6/30/2015* | 18,058 | 36% | 32,484 | 64% | \$15,816,746 | 76% | \$5,054,661 | 24% |
| Antidepressant | | | | | | | | | |
| | 7/1/2009-6/30/2010 | 22,358 | 25% | 66,509 | 75% | \$3,403,691 | 60% | \$2,290,816 | 40% |
| | 7/1/2010-6/30/2011 | 18,796 | 19% | 80,114 | 81% | \$2,900,028 | 51% | \$2,838,201 | 49% |
| | 7/1/2011-6/30/2012 | 13,520 | 13% | 92,124 | 87% | \$2,487,651 | 50% | \$2,528,206 | 50% |
| | 7/1/2012-6/30/2013 | 9,521 | 9% | 102,226 | 91% | \$2,274,479 | 47% | \$2,578,048 | 53% |
| | 7/1/2013-6/30/2014 | 5,017 | 5% | 98,423 | 95% | \$1,428,173 | 36% | \$2,514,924 | 64% |
| | 7/1/2014-6/30/2015* | 5,242 | 5% | 96,203 | 95% | \$1,349,207 | 38% | \$2,217,943 | 62% |
| Anti-anxiety | | | | | | | | | |
| | 7/1/2009-6/30/2010 | 293 | 1% | 52,690 | 99% | \$40,861 | 7% | \$585,858 | 93% |
| | 7/1/2010-6/30/2011 | 206 | <1% | 56,699 | 100% | \$38,126 | 6% | \$615,984 | 94% |
| | 7/1/2011-6/30/2012 | 153 | <1% | 59,655 | 100% | \$39,009 | 6% | \$622,672 | 94% |
| | 7/1/2012-6/30/2013 | 114 | <1% | 54,721 | 100% | \$44,039 | 8% | \$503,706 | 92% |
| | 7/1/2013-6/30/2014 | 120 | <1% | 52,292 | 100% | \$55,603 | 12% | \$424,190 | 88% |
| | 7/1/2014-6/30/2015* | 84 | <1% | 53,634 | 100% | \$61,460 | 14% | \$377,300 | 86% |

*Community Care Services (CCS) is added into totals for FY 2015 as a plan separate from QI.

Medicaid Fee-For-Service (FFS) Psychotropic Cost

| | | Total Number of Claims | | | | Total Expenditure | | | | Total No. Unique Utilizers |
|-----------------------|-----------------|------------------------|-----|---------|------|-------------------|-----|----------|------|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | \$ | % | \$ | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10* | 431 | 77% | 121 | 23% | \$173,656 | 94% | \$11,761 | 4% | 277 |
| | 7/1/10-6/30/11 | 243 | 68% | 112 | 32% | \$108,078 | 91% | \$10,354 | 9% | 201 |
| | 7/1/11-6/30/12 | 160 | 54% | 134 | 46% | \$71,790 | 81% | \$16,384 | 19% | 173 |
| | 7/1/12-6/30/13 | 10 | 24% | 32 | 76% | \$7,623 | 76% | \$2,371 | 24% | 20 |
| | 7/1/13-6/30/14 | 5 | 11% | 40 | 89% | \$3,443 | 42% | \$4,797 | 58% | 14 |
| | 7/1/14-6/30/15 | 4 | 11% | 31 | 89% | \$3323 | 46% | \$3869 | 54% | 10 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10* | 154 | 22% | 561 | 78% | \$17,861 | 52% | \$16,566 | 48% | 411 |
| | 7/1/10-6/30/11 | 77 | 15% | 449 | 85% | \$11,535 | 40% | \$15,732 | 60% | 324 |
| | 7/1/11-6/30/12 | 39 | 10% | 368 | 90% | \$6,100 | 38% | \$9,790 | 66% | 273 |
| | 7/1/12-6/30/13 | 0 | 0% | 102 | 100% | \$0 | 0% | \$2,269 | 100% | 49 |
| | 7/1/13-6/30/14 | 0 | 0% | 90 | 100% | \$0 | 0% | \$1,766 | 100% | 27 |
| | 7/1/14-6/30/15 | 0 | 0% | 38 | 100% | \$0 | 0% | \$783 | 100% | 10 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10* | 0 | 0% | 360 | 100% | \$0 | 0% | \$2,969 | 100% | 245 |
| | 7/1/10-6/30/11 | 0 | 0% | 263 | 100% | \$0 | 0% | \$3,142 | 100% | 202 |
| | 7/1/11-6/30/12 | 0 | 0% | 237 | 100% | \$0 | 0% | \$3,092 | 100% | 175 |
| | 7/1/12-6/30/13 | 0 | 0% | 78 | 100% | \$0 | 0% | \$687 | 100% | 52 |
| | 7/1/13-6/30/14 | 0 | 0% | 72 | 100% | \$0 | 0% | \$578 | 100% | 42 |
| | 7/1/14-6/30/15 | 0 | 0% | 32 | 100% | \$0 | 0% | \$302 | 100% | 25 |

*Fee-For-Service Aged, Blind and Disabled moved into QUEST Expanded Access on February 1, 2009.

AlohaCare QUEST Integration Psychotropic Cost

| | | Total Number of Claims | | | | Total Expenditure | | | | Total No. Unique Utilizers |
|-----------------------|----------------|------------------------|-----|---------|------|-------------------|-----|-----------|------|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | \$ | % | \$ | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 5,887 | 85% | 1,022 | 15% | \$2,182,797 | 94% | \$141,089 | 6% | 1,259 |
| | 7/1/10-6/30/11 | 6,545 | 81% | 1,460 | 19% | \$2,915,457 | 94% | \$183,521 | 6% | 1,410 |
| | 7/1/11-6/30/12 | 5,062 | 64% | 2,887 | 36% | \$2,614,657 | 83% | \$523,881 | 17% | 1,392 |
| | 7/1/12-6/30/13 | 3,517 | 46% | 4,138 | 54% | \$1,951,363 | 80% | \$484,644 | 20% | 1,220 |
| | 7/1/13-6/30/14 | 2,703 | 40% | 4,010 | 60% | \$2,323,691 | 86% | \$365,329 | 14% | 1,088 |
| | 7/1/14-6/30/15 | 147 | 22% | 511 | 78% | \$126,496 | 78% | \$35,079 | 22% | 646 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 4,380 | 26% | 12,376 | 74% | \$602,689 | 59% | \$423,742 | 41% | 3,355 |
| | 7/1/10-6/30/11 | 3,580 | 20% | 14,613 | 80% | \$509,803 | 46% | \$607,128 | 54% | 3,623 |
| | 7/1/11-6/30/12 | 2,303 | 12% | 16,663 | 88% | \$375,886 | 38% | \$621,367 | 62% | 3,593 |
| | 7/1/12-6/30/13 | 1,913 | 10% | 17,247 | 90% | \$274,955 | 36% | \$489,987 | 64% | 3,314 |
| | 7/1/13-6/30/14 | 712 | 4% | 17,915 | 96% | \$170,763 | 24% | \$553,019 | 76% | 3,192 |
| | 7/1/14-6/30/15 | 36 | <1% | 4,034 | 100% | \$8,389 | 14% | \$53,729 | 86% | 4,042 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 15 | <1% | 8,206 | 100% | \$2,505 | 3% | \$79,318 | 97% | 1,786 |
| | 7/1/10-6/30/11 | 18 | <1% | 8,111 | 100% | \$1,951 | 2% | \$80,947 | 98% | 1,894 |
| | 7/1/11-6/30/12 | 2 | <1% | 8,362 | 100% | \$247 | 0% | \$93,660 | 100% | 1,835 |
| | 7/1/12-6/30/13 | 0 | 0% | 6,731 | 100% | \$0 | 0% | \$61,849 | 100% | 1,734 |
| | 7/1/13-6/30/14 | 10 | <1% | 11,464 | 100% | \$3,219 | 2% | \$134,405 | 98% | 2,892 |
| | 7/1/14-6/30/15 | 0 | 0% | 1,607 | 100% | \$0 | 0% | \$22,000 | 100% | 1,602 |

HMSA QUEST Integration Psychotropic Cost

| | | Total Number of Claims | | | | Total Expenditure | | | | Total No. Unique Utilizers |
|-----------------------|----------------|------------------------|-----|---------|------|-------------------|-----|-----------|-----|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | \$ | % | \$ | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 11,615 | 83% | 2,430 | 17% | \$4,319,335 | 96% | \$160,146 | 4% | 2,127* |
| | 7/1/10-6/30/11 | 11,406 | 80% | 2,810 | 19% | \$4,847,964 | 98% | \$103,154 | 2% | 2,171 |
| | 7/1/11-6/30/12 | 9,978 | 66% | 5,290 | 34% | \$5,009,526 | 88% | \$664,503 | 12% | 2,221 |
| | 7/1/12-6/30/13 | 7,586 | 44% | 9,642 | 56% | \$4,626,576 | 86% | \$768,865 | 14% | 2,469 |
| | 7/1/13-6/30/14 | 7,055 | 45% | 8,755 | 55% | \$5,011,583 | 90% | \$555,836 | 10% | 2,429 |
| | 7/1/14-6/30/15 | 6,074 | 41% | 8,770 | 59% | \$4,866,243 | 89% | \$598,551 | 11% | 2,214 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 8,864 | 27% | 24,262 | 73% | \$1,185,654 | 58% | \$875,185 | 42% | 5,565* |
| | 7/1/10-6/30/11 | 7,410 | 19% | 30,843 | 81% | \$1,004,692 | 51% | \$947,123 | 49% | 6,199 |
| | 7/1/11-6/30/12 | 5,237 | 13% | 35,348 | 87% | \$904,502 | 54% | \$781,470 | 46% | 6,442 |
| | 7/1/12-6/30/13 | 3,870 | 8% | 43,422 | 92% | \$902,444 | 51% | \$880,628 | 49% | 7,428 |
| | 7/1/13-6/30/14 | 2,376 | 5% | 46,341 | 95% | \$620,624 | 42% | \$871,708 | 58% | 7,895 |
| | 7/1/14-6/30/15 | 2,279 | 4% | 50,516 | 96% | \$562,786 | 38% | \$909,438 | 62% | 8,276 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 18 | <1% | 11,536 | 100% | \$5,910 | 4% | \$137,248 | 96% | 2,360* |
| | 7/1/10-6/30/11 | 31 | <1% | 13,316 | 100% | \$6,803 | 6% | \$111,448 | 94% | 2,667 |
| | 7/1/11-6/30/12 | 18 | <1% | 13,545 | 100% | \$4,540 | 4% | \$116,889 | 96% | 2,488 |
| | 7/1/12-6/30/13 | 34 | <1% | 17,584 | 100% | \$10,378 | 8% | \$118,503 | 92% | 3,606 |
| | 7/1/13-6/30/14 | 44 | <1% | 21,076 | 100% | \$18,801 | 14% | \$115,739 | 86% | 4,461 |
| | 7/1/14-6/30/15 | 30 | <1% | 22,374 | 100 | \$37,788 | 29% | \$92,723 | 71% | 4,979 |

* The change of a pharmacy claims processor during this period results in some inconsistencies in data sets.

Kaiser QUEST Integration Psychotropic Cost

| | | Total Number of Claims | | | | Total Expenditure | | | | Total No. Unique Utilizers |
|-----------------------|----------------|------------------------|-----|---------|------|-------------------|-----|----------|-----|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | \$ | % | \$ | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 714 | 53% | 628 | 47% | \$210,251 | 98% | \$3,932 | 2% | 289 |
| | 7/1/10-6/30/11 | 853 | 54% | 730 | 46% | \$301,307 | 98% | \$6,176 | 2% | 360 |
| | 7/1/11-6/30/12 | 625 | 38% | 1,023 | 62% | \$258,603 | 89% | \$32,444 | 11% | 372 |
| | 7/1/12-6/30/13 | 404 | 24% | 1,307 | 76% | \$204,739 | 92% | \$17,232 | 8% | 335 |
| | 7/1/13-6/30/14 | 391 | 24% | 1,251 | 76% | \$242,048 | 94% | \$16,517 | 6% | 321 |
| | 7/1/14-6/30/15 | 252 | 22% | 905 | 78% | \$197,867 | 75% | \$65,471 | 25% | 353 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 497 | 8% | 5,857 | 92% | \$75,263 | 66% | \$38,422 | 34% | 1,181 |
| | 7/1/10-6/30/11 | 463 | 6% | 6,968 | 94% | \$80,249 | 66% | \$41,292 | 34% | 1,378 |
| | 7/1/11-6/30/12 | 485 | 5% | 8,444 | 95% | \$107,488 | 66% | \$55,350 | 34% | 1,589 |
| | 7/1/12-6/30/13 | 458 | 5% | 7,943 | 95% | \$124,731 | 71% | \$51,058 | 29% | 1,398 |
| | 7/1/13-6/30/14 | 248 | 4% | 6,811 | 96% | \$82,406 | 52% | \$77,015 | 49% | 1,358 |
| | 7/1/14-6/30/15 | 20 | <1% | 5,582 | 100% | \$8,669 | 14% | \$51,510 | 86% | 1,524 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 1 | <1% | 2,469 | 100% | \$147 | 3% | \$4,851 | 97% | 648 |
| | 7/1/10-6/30/11 | 1 | <1% | 2,789 | 100% | \$661 | 11% | \$5,101 | 89% | 777 |
| | 7/1/11-6/30/12 | 15 | <1% | 2,972 | 100% | \$5,503 | 53% | \$4,915 | 47% | 867 |
| | 7/1/12-6/30/13 | 13 | <1% | 2,646 | 100% | \$4,555 | 53% | \$4,095 | 47% | 758 |
| | 7/1/13-6/30/14 | 13 | <1% | 2,374 | 100% | \$6,912 | 65% | \$3,746 | 35% | 760 |
| | 7/1/14-6/30/15 | 2 | <1% | 2,758 | 100% | \$50 | 1% | \$3,843 | 99% | 898 |

Ohana Health Quest Integration Psychotropic Cost

| | | Total Number of Claims | | | | Total Expenditure | | | | Total No. Unique Utilizers |
|-----------------------|----------------|------------------------|-----|---------|------|-------------------|-----|-------------|-----|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | \$ | % | \$ | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 15,653 | 76% | 5,068 | 24% | \$7,510,115 | 92% | \$645,522 | 8% | 1,944 |
| | 7/1/10-6/30/11 | 18,771 | 76% | 6,008 | 24% | \$10,069,923 | 93% | \$701,013 | 7% | 2,164 |
| | 7/1/11-6/30/12 | 15,357 | 58% | 11,280 | 42% | \$9,537,668 | 75% | \$3,122,545 | 25% | 2,129 |
| | 7/1/12-6/30/13 | 9,555 | 35% | 17,735 | 65% | \$7,532,671 | 66% | \$3,936,457 | 34% | 2,216 |
| | 7/1/13-6/30/14 | 5,257 | 33% | 10,841 | 67% | \$4,600,691 | 67% | \$2,268,812 | 33% | 1,825 |
| | 7/1/14-6/30/15 | 9,918 | 35% | 18,459 | 65% | \$7,791,248 | 66% | \$4,050,672 | 34% | 2,424 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 5,462 | 26% | 15,688 | 74% | \$786,111 | 60% | \$519,290 | 40% | 2,559 |
| | 7/1/10-6/30/11 | 5,335 | 22% | 19,287 | 78% | \$754,409 | 49% | \$800,750 | 51% | 2,846 |
| | 7/1/11-6/30/12 | 4,310 | 16% | 22,277 | 84% | \$736,653 | 49% | \$774,715 | 51% | 2,856 |
| | 7/1/12-6/30/13 | 2,561 | 9% | 24,647 | 91% | \$631,605 | 42% | \$881,158 | 58% | 2,904 |
| | 7/1/13-6/30/14 | 1,256 | 6% | 18,716 | 94% | \$337,020 | 31% | \$752,440 | 69% | 2,510 |
| | 7/1/14-6/30/15 | 2,780 | 9% | 27,002 | 91% | \$688,288 | 42% | \$942,569 | 58% | 3,463 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 76 | <1% | 18,057 | 100% | \$21,672 | 11% | \$171,815 | 89% | 2,931 |
| | 7/1/10-6/30/11 | 49 | <1% | 19,805 | 100% | \$17,288 | 8% | \$191,471 | 92% | 3,032 |
| | 7/1/11-6/30/12 | 48 | <1% | 21,810 | 100% | \$18,985 | 8% | \$207,492 | 92% | 3,128 |
| | 7/1/12-6/30/13 | 51 | <1% | 18,104 | 100% | \$22,898 | 12% | \$173,596 | 88% | 2,838 |
| | 7/1/13-6/30/14 | 54 | 1% | 10,558 | 99% | \$22,505 | 17% | \$107,956 | 83% | 1,530 |
| | 7/1/14-6/30/15 | 51 | <1% | 19,791 | 100% | \$22,898 | 11% | \$185,664 | 89% | 3,188 |

United HealthCare QUEST Integration Psychotropic Cost

| | | Total Number of Claims | | | | Total Expenditure | | | | Total No. Unique Utilizers |
|-----------------------|----------------|------------------------|-----|---------|------|-------------------|-----|-------------|-----|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | \$ | % | \$ | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 7,268 | 71% | 3,010 | 29% | \$5,724,344 | 92% | \$500,395 | 8% | 2,045 |
| | 7/1/10-6/30/11 | 6,953 | 72% | 2,743 | 28% | \$7,049,618 | 95% | \$395,039 | 5% | 1,634 |
| | 7/1/11-6/30/12 | 5,760 | 58% | 4,046 | 42% | \$6,084,993 | 85% | \$1,032,928 | 15% | 1,493 |
| | 7/1/12-6/30/13 | 3,052 | 35% | 5,691 | 65% | \$4,532,005 | 83% | \$902,203 | 17% | 1,593 |
| | 7/1/13-6/30/14 | 2,132 | 34% | 4,212 | 66% | \$3,219,152 | 92% | \$290,152 | 8% | 1,500 |
| | 7/1/14-6/30/15 | 1,663 | 30% | 3,798 | 70% | \$2,831,569 | 89% | \$343,881 | 11% | 1,183 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 3,001 | 28% | 7,765 | 72% | \$736,113 | 64% | \$417,611 | 36% | 2,697 |
| | 7/1/10-6/30/11 | 1,931 | 20% | 7,954 | 80% | \$539,340 | 56% | \$426,176 | 44% | 2,093 |
| | 7/1/11-6/30/12 | 1,146 | 11% | 9,024 | 89% | \$357,022 | 56% | \$285,514 | 44% | 1,979 |
| | 7/1/12-6/30/13 | 719 | 8% | 8,865 | 92% | \$340,744 | 56% | \$272,948 | 44% | 2,301 |
| | 7/1/13-6/30/14 | 425 | 5% | 8,550 | 95% | \$217,360 | 46% | \$258,976 | 54% | 2,519 |
| | 7/1/14-6/30/15 | 147 | 2% | 9,031 | 98% | \$81,075 | 21% | \$297,782 | 79% | 2,532 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 183 | <1% | 2,062 | 99% | \$10,627 | 5% | \$189,657 | 95% | 2,640 |
| | 7/1/10-6/30/11 | 107 | <1% | 12,415 | 99% | \$11,423 | 5% | \$223,875 | 95% | 2,880 |
| | 7/1/11-6/30/12 | 70 | <1% | 12,729 | 99% | \$9,734 | 5% | \$196,624 | 95% | 2,813 |
| | 7/1/12-6/30/13 | 16 | <1% | 9,578 | 100% | \$6,208 | 4% | \$144,976 | 96% | 2,779 |
| | 7/1/13-6/30/14 | 8 | <1% | 6,748 | 100% | \$4,166 | 6% | \$61,766 | 94% | 1,917 |
| | 7/1/14-6/30/15 | 1 | <1% | 7,123 | 100% | \$724 | 1% | \$49,736 | 99% | \$1,949 |

Community Care Services (CCS)

| | | Total Number of Claims | | | | Total Expenditure | | | | Total No. Unique Utilizers |
|----------------|----------------|------------------------|-----|---------|------|-------------------|-----|-------------|-----|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | \$ | % | \$ | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/14-6/30/15 | 8,481 | 35% | 15,854 | 65% | \$9,467,571 | 71% | \$3,928,369 | 29% | 2,317 |
| Antidepressant | | | | | | | | | | |
| | 7/1/14-6/30/15 | 359 | 2% | 19,856 | 98% | \$98,992 | 10% | \$989,675 | 90% | 2,149 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/14-6/30/15 | 2 | <1% | 5,529 | 100% | \$419 | 1% | \$60,312 | 99% | 802 |

Discussion

This state fiscal year (FY) 2014-2015 report includes the term “QUEST Integration” to reflect the current Medicaid managed care plans for FY 2015. Several changes have occurred in this reporting period:

- QUEST and QUEST Expanded Access (from July 1, 2014 through December 31, 2014) transitioned into QUEST Integration (beginning January 1, 2015);
- On April 23, 2015, Act 020 was signed into law;¹ and
- Hawaii Community Care Services (CCS) information is reported for the first time.

The CCS transition began in April 2013 and was completed in April 2014; FY 2014-2015 is the first full year of CCS for reporting purposes. One plan reported significant decreases in unique utilizers, prescription count for both brand and generic medications, and their respective expenditures due to medication reporting under CCS instead of under QI. Verification is pending for data collection criteria for several plans as CCS data should not be included in reports for QUEST, QUEST Expanded Access or QI.

Previously Act 205, (SLH 2010),² effective on July 1, 2011, was implemented by the health plans during different quarters of FY 2010-2011.³ Fiscal Years 2011-2012, 2012-2013 and 2013-2014 are each full years of all plans complying with Act 205 (SLH 2010) without changes in the law or the program. Trends are noted. Data for FY 2009-2010, is represented for comparison purposes for the year prior to the implementation of Act 205, (SLH 2010).

Act 205 (SLH 2010) had minimal impact on anti-anxiety prescribing as the generic rate was initially extremely high. In FY 2009-2010, the prescribing rate was 99% and increased to 100% by FY 2010-2011 and continues at 100% through FY 2014-2015. Although total brand prescription number decreased, an increase was noted in the brand drug expenditures for all

programs combined when compared to FFS and QUEST plans in FY 2013-2014. One patient on long term brand can skew the numbers in a small database such as this one. Access to brand name medications remains available if needed.

For antidepressants, the generic prescribing rate continually increased from 75% in FY 2009-2010 to 95% in FY 2014-2015 and the percentage of total generic expenditures increased from 40% to 68%, respectively,⁴ for all programs combined. Access to brand was available after 2 generic failures are documented. The brand expenditures decreased from \$3.4 million in FY 2009-2010 to \$1.4 million in SFY 2014-2015 for all programs combined and percentage of total brand expenditures from 60% to 32%, respectively. Five percent of all antidepressant medications filled comprised the 32% of expenditures in FY 2014-2015 for all programs combined. Overall, the implementation of Act 205 (SLH 2010) was successful with positive outcomes.

Section 346-59.9, HRS, requires unrestricted antipsychotic prescribing. The generic prescribing rate increased from 23% in FY 2009-2010 to 62% in FY 2012-2013 and through today.⁵ Brand medications comprised 35% of the antipsychotic prescriptions that were filled and at 74% of the expenditures (\$25 of the \$34 million) in FY 2014-2015 for all programs combined. Several plans noted increased expenditures due to the cost of brand drugs increasing prior to patent expiration. In April 2015 antipsychotic medication, Abilify®, was available as a generic for the first time. Access to brand medication was not compromised.

¹ Act 020, Session Laws of Hawaii (SLH) 2015, amended Section 346-59.9, Hawaii Revised Statutes (HRS), by amending subsection (a) to read as follows:

“(a) This section shall apply only to the Medicaid managed care and fee-for-service programs administered by the department when the department or the department’s contracted health plan is the primary insurer. When the department is the secondary insurer, the department and its contracted health plans shall be responsible only for the secondary insurer’s share of any psychotropic medication covered by the primary insurer.”

² Access to brand medication is available after 2 generic failures are documented for antidepressant and anti-anxiety medications.

³ Different approaches and combinations were initiated by the different plans during SFY 2010-2011, such as the following: Preferred Drug Lists/Formulary Coverage, Prospective DUR edits, Point-Of-Sale messaging, Step Therapy, Prior Authorization, Provider Education and Call Center intervention.

⁴ Generic Luvox CR was available March 2013 and generic Cymbalta was available December 2013.

⁵ This shift was likely due to three (3) major brand antipsychotics becoming available in generic forms during SFY 2011-2012: Olanzapine for Zyprexa® as of November 2011; Quetiapine for Seroquel® as of March 2012 and Ziprasidone for Geodon® as of March 2012. In addition, to help ensure safety, the Med-QUEST Division (MQD) issued guidance to health plans regarding use of antipsychotics for Food and Drug Administration (FDA) approved diagnoses, FDA approved age criteria, Quantity Limits (FDA approved and dose optimization), Post-payment Reviews and Case Management.